Literature DB >> 16044250

Anti-phospholipid antibodies in serum from patients with Guillain-Barré syndrome.

G Nakos1, E Tziakou, L Maneta-Peyret, C Nassis, M E Lekka.   

Abstract

OBJECTIVE: The Guillain-Barré syndrome (GBS) is an acute inflammatory polyneuropathy related to autoimmunity. However, no conclusive etiological concept has yet been found. We examined the variation in autoantibodies to lipids in serum of GBS patients in response to the course of the disease but investigated titer modifications during treatment with gamma-globulin. DESIGN AND
SETTING: Prospective clinical study in a 14-bed general ICU. PATIENTS: Nine patients with GBS and nine controls were included in the study. MEASUREMENTS AND
RESULTS: Four blood samples were obtained before and after treatment. Serum samples, diluted 1:60, were tested by enzyme-linked immunosorbent assay for IgM, IgA, and IgG antibodies to phosphatidylcholine, phosphatidylinositol, cardiolipin, phosphatidic acid, phosphatidylserine, phosphatidylglycerol, phosphatidylethanolamine, sphingomyelin, and gangliosides. Anti-phospholipid antibodies of the IgM, IgA, and IgG families were detected in all GBS patients but in none of the controls. Phosphatidylinositol, cardiolipin, phosphatidylcholine, and phosphatidic acid were the main antigens. All patients developed anti-phosphatidylinositol antibodies of the IgM family and anti-cardiolipin antibodies of the IgA and IgG families. A decrease in the level of anti-phospholipid autoantibodies was observed after 1 day of treatment with gamma-globulin. Two days after ending gamma-globulin administration the IgG antibodies increased again.
CONCLUSIONS: Our findings suggest that in GBS there is an extensive immune reaction, which is altered after gamma-globulin treatment. Anti-cardiolipin and anti-phosphatidylinositol antibodies could be useful markers for the response to treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044250     DOI: 10.1007/s00134-005-2736-8

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  33 in total

1.  Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing.

Authors:  Emmanuel J Favaloro; Roger Silvestrini
Journal:  Am J Clin Pathol       Date:  2002-10       Impact factor: 2.493

Review 2.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

3.  Ganglioside-induced antiganglioside antibodies from a neuropathy patient cross-react with lipopolysaccharides of Campylobacter jejuni associated with Guillain-Barré syndrome.

Authors:  A Neisser; B Schwerer; H Bernheimer; A P Moran
Journal:  J Neuroimmunol       Date:  2000-01-03       Impact factor: 3.478

4.  Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies.

Authors:  E N Harris; A E Gharavi; C G Mackworth-Young; B M Patel; G Derue; G R Hughes
Journal:  Ann Rheum Dis       Date:  1985-04       Impact factor: 19.103

5.  Autoantibodies against all the phospholipids: a comparative systematic study with systemic lupus erythematosus and healthy sera.

Authors:  L Maneta-Peyret; C Previsani; Y Sultan; J H Bezian; C Cassagne
Journal:  Eur J Clin Chem Clin Biochem       Date:  1991-01

Review 6.  The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.

Authors:  Marinos C Dalakas
Journal:  Pharmacol Ther       Date:  2004-06       Impact factor: 12.310

7.  Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis.

Authors:  F J Vriesendorp; B Mishu; M J Blaser; C L Koski
Journal:  Ann Neurol       Date:  1993-08       Impact factor: 10.422

Review 8.  Anti-GQ1b ganglioside antibody in peripheral nervous system disorders: pathophysiologic role and clinical relevance.

Authors:  Konstantinos Paparounas
Journal:  Arch Neurol       Date:  2004-07

9.  Immune responses to myelin antigens in Guillain-Barré syndrome.

Authors:  R A Hughes; I A Gray; N A Gregson; M Kadlubowski; M Kennedy; S Leibowitz; H Thompson
Journal:  J Neuroimmunol       Date:  1984-08       Impact factor: 3.478

10.  Clinical presentation and outcome of Guillain-Barré and related syndromes in relation to anti-ganglioside antibodies.

Authors:  M Carpo; R Pedotti; S Allaria; F Lolli; S Matà; G Cavaletti; A Protti; S Pomati; G Scarlato; E Nobile-Orazio
Journal:  J Neurol Sci       Date:  1999-10-15       Impact factor: 3.181

View more
  5 in total

1.  Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker
Journal:  Intensive Care Med       Date:  2006-02-17       Impact factor: 17.440

Review 2.  Antiphospholipid antibodies in critically ill patients.

Authors:  Juliana Vassalo; Nelson Spector; Ernesto de Meis; Márcio Soares; Jorge Ibrain Figueira Salluh
Journal:  Rev Bras Ter Intensiva       Date:  2014 Apr-Jun

Review 3.  Neurologic Manifestations of the Antiphospholipid Syndrome - an Update.

Authors:  Miguel Leal Rato; Matilde Bandeira; Vasco C Romão; Diana Aguiar de Sousa
Journal:  Curr Neurol Neurosci Rep       Date:  2021-06-14       Impact factor: 5.081

Review 4.  Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored.

Authors:  Ying Wang; Shuang Sun; Jie Zhu; Li Cui; Hong-Liang Zhang
Journal:  Mediators Inflamm       Date:  2015-09-16       Impact factor: 4.711

Review 5.  Neuropsychiatric Manifestations of Antiphospholipid Syndrome-A Narrative Review.

Authors:  Yik Long Man; Giovanni Sanna
Journal:  Brain Sci       Date:  2022-01-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.